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Abstract
Background Viruses including Epstein–Barr virus (EBV), a
human equivalent of murine mammary tumour virus (MMTV) and
human papillomavirus (HPV) have been implicated in the
aetiology of human breast cancer. We report the presence of
HPV DNA sequences in areolar tissue and tumour tissue
samples from female patients with breast carcinoma. The
presence of virus in the areolar–nipple complex suggests to us
a potential pathogenic mechanism.
Methods Polymerase chain reaction (PCR) was undertaken to
amplify HPV types in areolar and tumour tissue from breast
cancer cases. In situ hybridisation supported the PCR findings
and localised the virus in nipple, areolar and tumour tissue.
Results Papillomavirus DNA was present in 25 of 29 samples
of breast carcinoma and in 20 of 29 samples from the
corresponding mamilla. The most prevalent type in both
carcinomas and nipples was HPV 11, followed by HPV 6. Other
types detected were HPV 16, 23, 27 and 57 (nipples and
carcinomas), HPV 20, 21, 32, 37, 38, 66 and GA3-1 (nipples
only) and HPV 3, 15, 24, 87 and DL473 (carcinomas only).
Multiple types were demonstrated in seven carcinomas and ten
nipple samples.
Conclusions The data demonstrate the occurrence of HPV in
nipple and areolar tissues in patients with breast carcinoma. The
authors postulate a retrograde ductular pattern of viral spread
that may have pathogenic significance.
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Introduction
Breast cancer is the most frequently diagnosed cancer
among women in the USA, and the incidence of breast car-
cinoma has increased by more than 40% over 25 years [1].
The aetiology of breast cancer remains unknown. Many risk
factors have been associated with the pathogenesis of this
disease, including family history, hormones, cigarette smok-
ing and alcohol consumption [2-7]. Hormones, cigarette
smoking and family history have also been demonstrated to
enhance infections with papillomaviruses, mainly the high-
risk human papillomavirus (HPV) types involved in the aeti-
ology of cervical carcinoma [8].
Viral infection as an aetiological factor has been addressed
in other studies. The data obtained from studies investigat-
ing the presence of viral sequences in breast cancer biop-
sies and cell lines have been controversial. A role for
herpes viruses, and specifically Epstein–Barr virus (EBV),
in the aetiology of this cancer has been questioned [9,10].
A human equivalent of the murine mammary tumour virus
(MMTV) has been described in breast tumours, as well as
in breast cancer cell lines [11]. These results have been
questioned and negated by others (R Schmidt and H zur
Hausen, unpublished results) [12]. Immortalisation of nor-
mal breast epithelial cells by the HPV types HPV 16 and
HPV 18 [13] has been used to study the functions of the
viral early genes E6 and E7 in different cellular pathways
[14-18]. However, the presence of HPV in malignant
tumours of the breast has been controversial. Several stud-
ies reported positive results [19-25], whereas others
reported negative results [26-28]. In the present study we
report the presence of HPV DNA in biopsy samples from
mammary carcinomas, as well as these viral sequences in
the tissue of the corresponding mamilla.
EBV = Epstein–Barr virus; HPV = human papillomavirus; MMTV = murine mammary tumour virus; PCR = polymerase chain reaction.Breast Cancer Research    Vol 7 No 1    de Villiers et al.
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Materials and methods
Samples and DNA extraction
Samples from breast tumour tissue for the HPV analysis
were supplied by two of the authors (RES and CEB). The
29 cases used for the retrospective study and demonstra-
tion of papillomavirus sequences were selected from rou-
tine mastectomy specimens undertaken in a course of
treatment for carcinoma of the breast. Case selection was
based on the availability of adequate nipple and tumour tis-
sue from the same patient and the presence of histological
features suggestive of HPV infection in nipple and areolar
sections. The patients, all female, ranged in age from 30 to
88 years, with an average age of 61.3 years. Twelve
tumours arose in the right breast and 17 in the left. Five
tumours were subareolar and 24 were located at a distance
from the nipple and areola. Tumours ranged in size from 6
mm to 15 cm. One patient received cytoxan chemotherapy
before surgery. In all other cases primary treatment was
surgical as represented by the specimen. One patient had
undergone contralateral mastectomy ten years earlier for a
localised breast cancer, which was judged clinically and
pathologically to represent a separate primary tumour.
Among the 29 patients there were three with remote histo-
ries of malignancy without evidence of recurrence (one
cutaneous malignant melanoma, one renal cell carcinoma
and one soft-tissue malignancy). One patient had under-
gone hysterectomy for high-grade cervical dysplasia. There
were no patients with documented cervical carcinoma. No
patients were immune-impaired or immunosuppressed.
Formalin-fixed paraffin-embedded samples from both the
nipple (n = 29) and the carcinoma of the breast (n = 29)
from the same patient were sectioned, and the total DNA
was extracted from each sample. Great care was taken dur-
ing sectioning to avoid any contamination between sam-
ples. Two different individuals sectioned the blocks in
several small random groups at different time intervals over
a period of one week. The microtome was cleaned thor-
oughly and exposed to ultraviolet between samples; in
addition, new blades were used for each sample. Depar-
affinisation was performed by rotation overnight in 1 ml of
xylene, followed by centrifugation and subsequent removal
of the supernatant. This step was repeated twice (each for
one hour) with fresh xylene. The xylene was in turn removed
by rotation in 1 ml of 100% ethanol for one hour followed
by centrifugation and subsequent replacement of the
supernatant with 90% ethanol for 45 min, and repeated by
steps of 80% ethanol for 45 min and 70% ethanol for 45
min. Samples were freeze-dried, and total cellular DNA was
extracted as described previously [29]. The DNA was
digested with Proteinase K and subjected to extraction with
phenol followed by extraction with chloroform/isoamyl alco-
hol. The extracted DNA was precipitated with ethanol and
the pellet was resuspended in 10 mM Tris/HCl, pH 8.0.
PCR analysis and cloning
DNA (50–100 µg) of each sample was amplified by
polymerase chain reaction (PCR). The quality of the DNA
obtained from the fixed samples was controlled by amplifi-
cation with primers to detect the β-actin gene [30]. The
primers RS42 and KM29 were initially used to amplify the
536-base-pair fragment of the β-actin gene. If this size of
fragment could not be amplified, the primers PC03 and
PC04 were used to amplify the 110-base-pair (bp) frag-
ment of the β-actin gene. Papillomavirus sequences were
amplified by three different methods, each targeting highly
conserved regions within the L1 open reading frame of
papillomaviruses. These included the GP5+/GP6+ primers
[31], the CP primers using modified conditions as previ-
ously described [32] and the FAP primers [33]. All three
primer combinations are routinely used on individual sam-
ples tested in our laboratory. We initially modified the PCR
conditions for each described method to include the ampli-
fication of the largest number of individual HPV types pos-
sible. Cloned DNA of each known HPV type was used to
optimise these conditions. Amplification with the GP prim-
ers was performed in 2 mM MgCl2 using 40 cycles with an
annealing temperature of 40°C. The expected size of the
amplicon was 140–150 bp. The expected size with the
FAP primers is 480 bp after 45 cycles in 3.5 mM MgCl2 and
an annealing temperature of 50°C. The nested amplifica-
tion approach with the CP primers results in an amplicon
size of 370–400 bp. The initial amplification was performed
in 2 mM MgCl2 and 40 cycles at 50°C annealing tempera-
ture, after which an aliquot was re-amplified with nested
primers but with the same PCR conditions. All amplicons
were eluted after gel electrophoresis, purified and cloned.
At least ten fragments of each amplicon were sequenced.
Sequencing was performed with either the Sequenase 2.0
DNA Sequencing Kit (USB, Cleveland, OH) or an ABI
Model Sequencer with Big Dye Terminator chemistry (Per-
kin Elmer Applied Biosystems Division, Dreieich, Germany).
All precautions were taken to avoid contamination before or
during extraction of the DNA from the embedded formalin-
fixed samples. After initial results had been obtained, a sec-
ond sectioning was performed on the same embedded
samples and DNA was again extracted to ensure that no
contamination had taken place during the first round of
experiments. This second round of analyses was performed
in different rooms and by different individuals.
Sequence analysis
Sequences were compared with all available data banks
with the aid of the Husar software package (Deutsches
Krebsforschungszentrum).
In situ hybridisation
In situ hybridisation was performed as described by
Kawase and colleagues [34]. Papillomavirus probes were
digoxigenin-labelled by PCR in accordance with theAvailable online http://breast-cancer-research.com/content/7/1/R1
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manufacturer's instructions (PCR DIG Probe Synthesis Kit,
catalogue no. 1636090; Roche, Mannheim, Germany). The
FAP primers were used to label HPV 6 and HPV 11 DNA
and the CP primers to label HPV 16 DNA. Denaturation
was performed in a Biozym cycler for 5 min at 95°C fol-
lowed by hybridisation overnight at 37°C under stringent
conditions as described previously [35]. This was followed
by washing with solutions in accordance with instructions
in the Genpoint Kit (catalogue no. K0620; Dako, Hamburg,
Germany). Anti-digoxigenin-AP antibodies (anti-digoxi-
genin-AP, Fab fragments, catalogue no. 1093274; Roche),
blocking reagent (catalogue no. 1096176; Roche) and
Nitro Blue Tetrazolium/5-bromo-4-chloroindol-3-yl phos-
phate (catalogue no. 1681451; Roche) were applied for
visualisation of the signals. Sections from each sample
were used for in situ hybridisation. Reading of the samples
was blinded and performed by one of us (HzH).
Results
Nipple specimens were reviewed and selected by two of us
(CEB, RES) for histological features consistent with human
papillomavirus infections. Features identified included epi-
thelial hyperplasia, hypergranulosis, parakeratosis, and dis-
torted nuclear shape associated with nuclear clearing and
pyknosis suggestive of koilocytosis. In addition, squamous
metaplasia of lactiferous ducts and shedding of metaplas-
tic cellular elements into lactiferous ducts and sinuses were
noted (Fig. 1). In addition to the 29 invasive carcinomas,
ductal carcinoma in situ was identified in lactiferous ducts
in four samples and small benign papillomas were present
in three samples. Most invasive carcinoma samples (18 of
29) displayed a duct cell carcinoma pattern (Table 1).
Other types included medullary carcinoma (five cases),
tubular carcinoma (three cases), lobular carcinoma (two
cases) and mucinous carcinoma (one case). DNA
extracted from the samples taken from the nipple and the
corresponding carcinoma of each breast (29 pairs) was
analysed by PCR for the presence of papillomavirus
sequences. The quality of the DNA was controlled by
amplification of the β-actin gene. The 536-base-pair frag-
ment of this gene was amplified in 47 of 58 samples. The
110-base-pair fragment was amplified in the remaining 11
samples (Table 2). Intact papillomavirus particles are resist-
ant to degeneration. Extraction of DNA from fixed tissue
can harbour intact viral genomes even under conditions in
which the cellular DNA has been degraded. The three dif-
ferent methods used for amplification of the papillomavirus
DNA were chosen to ensure amplification of all known pap-
illomavirus types, as well as putative new types. All three
primer combinations (GP, CP and FAP) are routinely used
on individual samples tested in our laboratory. We initially
modified the PCR conditions for each described method to
include the amplification of the largest number of individual
HPV types possible. Cloned genomic DNA of each known
HPV type was used to optimise these conditions. The GP
primers have been designed to amplify the majority of pap-
illomavirus types associated with mucosal lesions. The FAP
primers, in contrast, were initially designed to amplify the
majority of papillomavirus types associated with cutaneous
lesions. The amplicon size described is 480 bp, but in our
hands smaller fragments identified as papillomavirus
sequences (after cloning and sequencing) were also gen-
erated, depending on the HPV type. The CP primers were
originally designed to amplify all the epidermodysplasia ver-
ruciformis-associated HPV types, but under modified con-
ditions a large spectrum of mucosal types are amplified as
well. Combining the three methods with the modified PCR
conditions allows us to amplify all known HPV types with
more or less equal efficiency. The amplicons generated,
using any of the described methods, often constitute cellu-
lar sequences depending on the viral load of the sample.
Normal breast and areolar tissue was not available for use
as control samples. The described methods of testing have
been used routinely in our laboratory over several years in
the analyses of tissues from a large variety of organs. We
have analysed large numbers of samples from benign and
malignant tumours of the oesophagus, head and neck and
skin, as well as normal skin tissue for the presence of pap-
illomavirus DNA with identical methods. HPV positivity var-
ied depending on the type of tumour and normal tissue
[29,36-38] (E-MdV, unpublished data). The present study
describes the first series of tissue of the breast analysed in
our laboratory for the presence of papillomavirus DNA.
Sequence analyses showed that 25 (86%) of the breast
carcinoma samples and 20 (69%) of the samples from the
mamilla harboured papillomavirus sequences. The results
for each sample using each of the primer combinations are
presented in Table 2. Only one pair of samples were both
negative for HPV DNA. HPV DNA was present in 17 (59%)
pairs of samples, namely nipple as well as carcinoma,
whereas papillomavirus DNA was detected only in the car-
cinomatous tissue in eight cases (28%) and only in the nip-
ple in three cases (10%) (Table 3). HPV 11 DNA was
present in both carcinoma and nipple samples in seven
cases, HPV 6 in one case and HPV 57 in two cases. The
most prevalent HPV types were HPV 11 (19 carcinomas
and 8 nipples) followed by HPV 6 (7 carcinomas and 6 nip-
ples) (Table 4). Other HPV types detected were HPV 16 (2
carcinomas and 3 nipples), HPV 57 (2 carcinomas and 3
nipples), HPV 27 (2 carcinomas and 4 nipples), HPV 66 (2
nipples), candHPV 87 (4 carcinomas), HPV 37 (4 nipples)
and the putative new HPV type DL250 (HPV 9-related) in
two carcinomas. HPV types detected in single samples of
the nipple were HPV 20, 21, 23, 32, 38 and GA3-1 (HPV
8-related) and HPV 3, 15, 23, 24 and DL473 (HPV 15-
related) in carcinoma samples. Multiple HPV types were
demonstrated in eight carcinomas (24%) and ten nipple
(34.5%) samples.Breast Cancer Research    Vol 7 No 1    de Villiers et al.
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Figure 1
Histological features of the carcinomatous breast (magnification × 100) Histological features of the carcinomatous breast (magnification × 100). Detailed histology of (a) is seen in (b–d). AS, anucleate squames; aster-
isks, interstitial lymphocytic infiltrates; G, galactophore; K, keratin; LS, lactiferous sinus; LD, lactiferous duct; SG, sebaceous gland (tangenial cut); 
SGD, sweat gland duct; SH, simple epithelial hyperplasia; PH, papillary epithelial hyperplasia.Available online http://breast-cancer-research.com/content/7/1/R1
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In situ hybridisation was performed on all samples that had
previously been positive by PCR amplification for HPV 6,
HPV 11 or HPV 16. Positive signals were clearly distin-
guishable from the surrounding negative tissue (Fig. 2). All
carcinoma samples that had been negative for one of these
three HPV types by PCR were also subjected to in situ
hybridisation with each of the respective labelled HPV
probes. No positive hybridisation signal was observed in
any of these samples. In situ hybridisation supported the
presence of HPV 6, 11 and 16 in nipple and areolar sam-
ples and in all tumour tissue in which these type-specific
HPV sequences were detected by PCR analysis.
Discussion
The ubiquitous distribution of papillomavirus infections of
the skin and genital and oral mucosa has been documented
[39-41]. Infection with specific papillomavirus types has
been shown to be a necessary but not sufficient cause in
the pathogenesis of malignant genital tumours. The malig-
nant tumours generally develop after long latency periods
during which additional cellular modifications occur within
the infected cell [8]. The E6 and E7 genes of the most prev-
alent high-risk HPV types, HPV 16 and HPV 18, modulate
cellular pathways, thereby regulating proliferation and cell
survival [8,42]. In contrast, the E6 and E7 proteins of the
low-risk types, HPV 6 and HPV 11, do not influence these
cellular pathways in the same manner, although they have
occasionally been demonstrated in premalignant and
malignant tumours. Additional cofactors are probably
needed to modulate cellular proteins so as to immortalise
and transform the infected cells [8]. The mechanism
through which other HPV types, mainly associated with
cutaneous lesions, might be involved in the pathogenesis of
tumours has received little attention. However, preliminary
data indicate that several molecular pathways are probably
followed, depending on the HPV type involved [43].
The detection of papillomavirus infections in tissues largely
depends on the method used. Described methods vary
greatly in their sensitivity and specificity. The HPV types
HPV 6, 11, 16, 18, 31, 33, 35, 39, 52 and 58 are frequently
associated with genital lesions and are therefore most
often targeted for HPV detection. Tests to demonstrate any
of the 96 characterised HPV types in tissues require exten-
sive analyses, including the sequencing of cloned amplim-
Table 1
Samples analysed for HPV sequences
Carcinoma type Location Number tested HPV DNA positive
Invasive ductal Carcinoma 18 16
Nipple 11
Medullary Carcinoma 5 4
Nipple 3
Tubular Carcinoma 3 3
Nipple 3
Lobular Carcinoma 2 1
Nipple 2
Mucinous Carcinoma 1 1
Nipple 1
Total carcinoma Carcinoma 29 25 (86%)
Nipple 20 (69%)
HPV, human papillomavirus.
Figure 2
Papillomavirus sequences detected by in situ hybridisation Papillomavirus sequences detected by in situ hybridisation. (a) Case 
10012, in the nipple epithelium (magnification × 40). (b) Case 10041, 
in the nipple epithelium (magnification × 40). (c) Case 10012, in 
tumour tissue (magnification × 100). (d) Case 10014, in tumour tissue 
(magnification × 100).Breast Cancer Research    Vol 7 No 1    de Villiers et al.
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ers. Most published studies therefore used methods
restricted to the detection of specific, single, or combina-
tions or groups of HPV types. The use of type-specific
primers may increase the number of positive samples but is
biased with regard to the HPV types involved, because
other HPV types present cannot be detected.
The present study investigated breast samples by using
DNA PCR amplification of two conserved regions within
the L1 open reading frame of the papillomavirus genome.
Two of the primer combinations used (CP and GP primers)
amplify an overlapping region within the L1 open reading
frame. By using all three primer combinations to amplify the
DNA of a single sample we are able to detect all known
HPV types and also putative new HPV types. In addition,
the cloning of the amplified product, in combination with
sequencing of the cloned inserts, allows us to distinguish
individual HPV types present in one sample, including mul-
tiple infections in one sample. Studies applying the tech-
niques described here have demonstrated a larger
spectrum of papillomavirus types associated with different
types of benign and malignant tumours and argue that the
historical grouping into 'mucosal' and 'cutaneous' HPV
types can no longer be upheld [44]. We are not aware of
any study outside our group that has analysed tissues for
the presence of infection by any HPV types as extensively
as the study described here.
Other investigators have analysed nipple and areolar spec-
imens for the presence of HPV DNA. HPV 6/11 was
detected in one of 20 papillomas of the nipple, whereas ten
nipple duct adenomas were negative [45] and seven low-
risk and high-risk HPV types were not present in 20 cases
of Paget's disease of the nipple [46]. Single cases of pap-
illomas of the nipple resembling condylomata acuminata
harboured HPV 6 DNA [47] and HPV 41 DNA [48].
Reports on the detection of HPV 16, HPV 18 and/or HPV
33 DNA in breast carcinoma samples range between 11%
and 68% positivity [19-25]. The present study detected
HPV 16 DNA in 7% of the carcinoma and in 10% of the nip-
ple samples. The only other high-risk HPV type, HPV 66,
was present in two samples from the nipple. The reasons
for the differences in published reports are unclear, but may
be attributed to numbers of samples tested, methodologi-
cal differences or the demographics of the samples tested.
In contrast, several other studies failed to demonstrate HPV
sequences in tumours of the breast: all of 15 papillomas
and 28 breast carcinoma samples were negative for HPV
6, 16 and 18 DNA [26], no HPV 16 and HPV 18 DNA
could be detected in 26 fine needle aspirates and four
breast carcinoma biopsies [28], and no HPV DNA was
found in 80 samples of breast carcinomas [27]. HPV 16
and HPV 18 oncogenes immortalise normal human mam-
mary cells under in vitro conditions [14-18]. It is unclear
whether these data truly represent the in vivo situation.
The present study detected papillomavirus sequences in
86% (25/29) of the breast carcinoma samples and 69%
(20 of 29) of the nipple samples. HPV 6 and HPV 11 infec-
tions were most prevalent in our collection of samples.
Either of the two HPV types was present in 20 of 29 (69%)
of the breast carcinoma biopsies and in 12 of 29 (41%) of
the samples of the mamilla. We detected the simultaneous
presence of more than one HPV type in about one-third of
the samples. HPV types associated with mucosal lesions,
and also several associated with skin lesions, were
detected. HPV 27 and HPV 57 are closely related HPV
types. HPV 27 is very frequently found in cutaneous warts,
whereas HPV 57 has been demonstrated in mucosal and
cutaneous lesions [49]. Several other HPV types found in
the breast samples have historically been associated with
the rare hereditary disease epidermodysplasia verruci-
formis but have more recently been shown in non-
melanoma skin cancers and their precursors in both immu-
nosuppressed and immunocompetent patients [44].
The confirmation of PCR-derived evidence of HPV
sequences in nipple, areolar and tumour tissue by in situ
hybridisation in our hands lends substantive support to the
conjecture that viral sequences are present and not an arte-
fact in the tissues we have examined. The absence of HPV
DNA in several samples, as well as the detection of differ-
ent HPV types in the carcinoma versus the nipple of the
same patient, might be attributed to the viral load at the time
of sampling in combination with the sensitivity of the tests
performed. The tissue sections also harboured unaffected
tissue, leading to the dilution of virus-containing cells. In
addition, the amplification of viral DNA by PCR with degen-
erate or consensus primers will detect replicating viral
sequences and is not sensitive enough to detect all individ-
ual HPV types with equal sensitivity in a mixed population
of cells. The in situ hybridisation technique is also less sen-
sitive and will not detect a single viral genome copy per cell.
HPV 6 and HPV 11 are regarded as low-risk HPV types
because they have only rarely been demonstrated in prema-
lignant or malignant tissue, and the early genes E6 and E7
do not immortalise primary keratinocytes in vitro [50]. HPV
6 DNA has been found in carcinomas [51,52] and giant
condylomas (Buschke–Löwenstein tumours) [53,54]. The
molecular mechanism by which these low-risk HPV types
induce or participate in the transformation of cells has not
been resolved. Duplications of the long control region [54-
57], minimal sequence dissimilarities [58,59] and integra-
tion [60] of HPV 6 and/or HPV 11 genomes have been
shown in malignant tissue.
The mere presence of the low-risk HPV 6 and 11 in most of
the mamillae and in the concomitant breast carcinoma sam-
ples does not prove its role in the aetiology of the disease,
although it merits further investigation. Unfortunately,Available online http://breast-cancer-research.com/content/7/1/R1
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Table 2
Presence of HPV DNA: results obtained after amplification with respective primers
Carcinoma type Patient number Location β-actin HPV
KM29/RS42 
(536 bp)
PC03/PC04 
(110 bp)
GP CP FAP
Invasive duct 
cell
1 Carcinoma + HPV11 - HPV11
Nipple + HPV16 HPV27 HPV11, HPV57
2 Carcinoma + HPV11 - HPV11
Nipple - + HPV11 - HPV6, HPV11
3 Carcinoma + - - HPV11
Carcinoma + HPV16 HPV27 -
4 Carcinoma + - - HPV11
Nipple - + - - -
5 Carcinoma + - - HPV 11
Nipple + - - HPV3, HPV11, 
HPV20, HPV21
6 Carcinoma + HPV11, HPV16 HPV6, HPV27, 
HPV57
HPV3, HPV6, 
HPV57
Nipple + - - HPV6, HPV11, 
HPV57
7 Carcinoma + - - -
Nipple + - - -
8 Carcinoma + - DL250 (HPV9-
related)
-
Nipple + - - -
9 Carcinoma + - DL473 (HPV15-
related)
-
Nipple + - - -
10 Carcinoma + - HPV6 -
Nipple + - - -
11 Carcinoma + - HPV23 -
Nipple + - GA3-1 (HPV8-
related)
-
12 Carcinoma + HPV11 - -
Nipple + - HPV37 -
13 Carcinoma - + HPV11 - HPV11
Nipple - + - - HPV6
14 Carcinoma - + - HPV 24 -
Nipple + - - -
15 Carcinoma + HPV11 HPV6, DL250 HPV11, HPV87
Nipple + HPV66 - -
16 Carcinoma + - - HPV11
Nipple + - - -
17 Carcinoma + - - -Breast Cancer Research    Vol 7 No 1    de Villiers et al.
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Nipple - + HPV6, HPV66 HPV37 -
18 Carcinoma + HPV11 - HPV11
Nipple + HPV6 HPV37 -
Medullary 19 Carcinoma + HPV11 - HPV11
Nipple - + - - HPV11
20 Carcinoma + - - -
Nipple + HPV11 - -
21 Carcinoma + HPV11 HPV6 HPV6, HPV87
Nipple + - HPV23 -
22 Carcinoma + HPV11 HPV6 HPV6, HPV87
Nipple + - - -
23 Carcinoma + - HPV 6 HPV11
Nipple + - - -
Tubular 24 Carcinoma + - - HPV57
Nipple - + HPV6, HPV57 HPV6, HPV57 HPV6, HPV57
25 Carcinoma + - - HPV11
Nipple - + HPV16, HPV27 - HPV11
26 Carcinoma + HPV11 HPV15 HPV87
Nipple - + - HPV27, HPV37 -
Lobular 27 Carcinoma + HPV11, HPV16 HPV27 -
Nipple + - - HPV11
28 Carcinoma + - - -
Nipple + - - -
Mucinous 29 Carcinoma - + - HPV6 HPV11
Nipple + - HPV38 -
bp, base pairs; HPV, human papillomavirus.
Table 3
Papillomavirus sequences demonstrated
Tumor pairs Number HPV typesa
Carcinoma+ nipple+ 17 Same type in both samples: 11 (7×)b, 6 (1×)b, 57 (2×)
Different types: 3, 15, 16, 20, 21, 23, 27, 37, 38, 66, 87, DL250, DL473, GA3-1
Carcinoma- nipple+ 3 6, 11, 32, 37, 66
Carcinoma+ nipple- 8 6, 11, 24, 87, DL250, DL473
Carcinoma- nipple- 1
aInfection with multiple human papillomavirus (HPV) types was demonstrated in eight carcinoma samples (27.6%) and ten nipple samples 
(34.5%).
bOne pair harboured HPV 6, HPV 11 and HPV 57 DNA.
Table 2 (Continued)
Presence of HPV DNA: results obtained after amplification with respective primersAvailable online http://breast-cancer-research.com/content/7/1/R1
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because of the previous fixation of our samples, RNA from
these tumours was not available for the detection of viral
transcripts as additional support of our results. Relatively
few studies have been performed in an attempt to unravel
the intracellular mechanisms through which HPV 6 or 11
may immortalise cells, and information is still fractional in
comparison with data on the high-risk HPV types. Introduc-
tion of the HPV 6 E6 into normal mammary cells leads to
immortalisation and reduced levels of the p53 protein [61].
Binding of the HPV 6 E6 protein modulates the function of
the cellular proteins Bak [62], Gps2 [63] and Zyxin [64].
Additional in vitro studies investigating the influence of hor-
mones, smoke adducts and genetic factors on the interac-
tion of the HPV 6 and 11 proteins with cellular proteins
should provide valuable information on a possible role for
HPV 6 and 11 in the pathogenesis of breast carcinoma.
The data presented in this study also indicate a strong need
for epidemiological studies correlating HPV, cigarette
smoking, hormone use and family history to substantiate in
vitro findings.
This study suggests that human papillomavirus may infect
the epithelium of the nipple and areola. Human papillomavi-
rus infection may be identified with recognisable histologi-
cal features comparable to human papillomavirus infection
at other sites. Furthermore, this study is consistent with a
pathogenic mechanism involving transfer in a retrograde
fashion via the nipple, areola, lactiferous ducts and sinuses
of the human papillomavirus. If confirmed, the pathogenic
mechanism proposed may have significant implications for
the prevention and treatment of breast carcinoma and the
identification of individuals at risk for carcinoma develop-
ment. Examination of cellular samples of nipple and areola
inclusive of cytological examination and methods for
identifying the presence of human papillomavirus might aid
early diagnosis and perhaps therapy.
Conclusions
The data demonstrate the occurrence of HPV in nipple and
areolar tissues in patients with breast carcinoma. The pres-
ence of papillomavirus DNA in most mamillae and concom-
itant breast carcinoma samples merits further investigation.
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